Presentations will include overviews of the company's KB001-A development program to treat Pseudomonas aeruginosa (Pa) infection and KB004 development program in hematological malignancies. KB001-A is an anti-PcrV monoclonal antibody (mAb) fragment, which KaloBios is developing for the prevention and treatment of Pa lung infection in cystic fibrosis (CF) patients. The company is currently conducting a 180 patient Phase 2 study of KB001-A in CF subjects with chronic Pa lung infections. KB004 is an anti-EphA3 mAb, with potential to treat both hematologic malignancies and solid tumors. KaloBios is conducting a Phase 1 dose escalation study of KB004 in hematologic malignancies seeking a maximum tolerable dose, and commenced the Phase 2 expansion portion of the study in early 2014.
Individuals may access a live audio webcast of the Jefferies presentation by visiting the event URL at: http://wsw.com/webcast/jeff82/KBIO. A replay of the webcast will be available on this site for 90 days following the live event.
About KaloBios
Currently, KaloBios has advanced three programs to clinical development:
All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.
For more information on
Forward Looking Statements
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and statements regarding the company's clinical development of KB001-A, KB004 and KB003. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the potential timing and outcomes of clinical studies of
KB001-A and KB004 undertaken now or in the future; the potential, if any, for future development of KB003; the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, visit http://www.kalobios.com.
Contact:
Chief Financial Officer
(650) 243-3114
[email protected]
Media Contact:
Tel: (415) 821-2413
Mobile: (415) 690-0210
[email protected]
Logo - http://photos.prnewswire.com/prnh/20130225/MM66380LOGO
SOURCE
News Provided by Acquire Media